Ajanta Pharma Ltd on Monday reported a 20% year-on-year rise in consolidated net profit at ₹260 crore for the quarter ended September 30, 2025, compared with ₹216 crore in the same period last year.

Revenue from operations grew 14% to ₹1,354 crore from ₹1,187 crore in the year-ago quarter, the company said in a filing with the stock exchanges. EBITDA stood at ₹328 crore, up 5% year-on-year, with margins at 24%.

The company’s Board of Directors approved the first interim dividend for FY26 of ₹28 per equity share (face value ₹2), amounting to ₹349.82 crore. The record date for the dividend has been fixed as November 10, with payment on or after November 20, 2025.

Ajanta Pharma said the growth was driven by a strong performance in its branded generics and US generics businesses. Revenue f

See Full Page